Drug Profile
Research programme: mucin 1 inhibitors - Minerva Biotechnology
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Minerva Biotechnology
- Class Antibodies; Small molecules
- Mechanism of Action Mucin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 10 Oct 2013 Preclinical development is ongoing in USA
- 12 May 2009 Early research in Breast cancer in USA (unspecified route)